Beam Therapeutics Inc.
Every calculator, already run for BEAM
Open the full toolkit →You have the numbers on BEAM. Get the argument.
A written report on which of these readings actually decide the outcome for Beam Therapeutics Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
15 analysts covering BEAMAnalyst Price Target Disagreement for Beam Therapeutics Inc.
Wall Street's bull case implies +233% from the current price; the bear case implies +8%. A 225% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BEAM
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Beam Therapeutics Inc.
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE…
BEAM — frequently asked
Is BEAM a buy right now?
Wall Street's consensus rating on Beam Therapeutics Inc. is Strong Buy across 15 analysts, with a mean price target of $52.15 (+117% vs. the current $23.99). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is BEAM's next earnings date?
Beam Therapeutics Inc. is next scheduled to report earnings around Nov 3, 2026. A full BEAM research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Beam Therapeutics Inc.?
Analysts covering Beam Therapeutics Inc. (BEAM) range from a bear-case target of $26.00 to a bull-case high of $80.00, with a mean consensus target of $52.15 across 13 analysts. The spread of $54.00 (225% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Beam Therapeutics Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Beam Therapeutics Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BEAM research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Beam Therapeutics Inc., in minutes. 3 free reports included with every account — no credit card required.